20 Jun 2013
GlaxoSmithKline is investing €17.5 million in a French-based venture capital fund which finances innovation in rare diseases in Europe, which according to the article reflects an increasing trend amongst big pharma to invest in startups and in the rare disease field.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024